BCLSI
BLUE

Bain Capital Life Sciences Investors’s bluebird bio BLUE Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-26,909
Closed -$5.38M – 35
2021
Q4 		$5.38M Sell
26,909
-14,638
-35% -$3.45M 0.43% 27
2021
Q3 		$7.24M Hold
41,547
– – 0.45% 25
2021
Q2 		$17.2M Hold
41,547
– – 1.13% 20
2021
Q1 		$16.2M Buy
+41,547
New +$20.5M 0.92% 21

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bain Capital Life Sciences Investors's BLUE Position: Q1 2022 in Review

Bain Capital Life Sciences Investors sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 26,909 shares — an estimated $5.38M sold.

Bain Capital Life Sciences Investors first reported a position in BLUE in Q1 2021 and held it in 4 quarters. The position peaked at $17.2M in Q2 2021. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

  • Bain Capital Life Sciences Investors reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 26,909 bluebird bio shares in Q1 2022, an estimated $5.38M.
  • Bain Capital Life Sciences Investors first reported a position in bluebird bio in Q1 2021 and held it in 4 quarters.
  • Bain Capital Life Sciences Investors's bluebird bio position peaked at $17.2M in Q2 2021.
  • 174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2022, filed 16 May 2022.